BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
- Conditions
- Advanced MelanomaMetastatic Melanoma
- Interventions
- Biological: Nivolumab
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 170
- Registration Number
- NCT01621490
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇳🇱Local Institution - 0016, Amsterdam, Netherlands
🇺🇸University Of Chicago, Chicago, Illinois, United States
Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC
- Conditions
- HIV
- Interventions
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3
- Registration Number
- NCT01620944
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- Biological: Pegylated interferon lambda (pegIFNλ)Biological: Pegylated interferon alfa-2a (pegIFNα-2a)
- First Posted Date
- 2012-06-11
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 880
- Registration Number
- NCT01616524
- Locations
- 🇺🇸
Precision Research Institute, Llc, San Diego, California, United States
🇺🇸Medical Associates Research Group, San Diego, California, United States
🇺🇸Orlando Infectious Disease Center, Orlando, Florida, United States
A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis
- Conditions
- Healthy Subjects and Atopic Dermatitis Subjects
- Interventions
- Biological: BMS-981164Biological: Placebo matching with BMS-981164
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 93
- Registration Number
- NCT01614756
- Locations
- 🇬🇧
Local Institution, Nottingham, United Kingdom
Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
- Conditions
- Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
- Interventions
- Biological: Ipilimumab
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT01611558
- Locations
- 🇺🇸
AdventHealth Cancer Institute, Orlando, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Georgia Regents University, Augusta, Georgia, United States
Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects
- Conditions
- Healthy Adult Normals
- Interventions
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 115
- Registration Number
- NCT01605994
- Locations
- 🇺🇸
Clinilabs, Inc., New York, New York, United States
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
- Conditions
- HIV
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT01605084
- Locations
- 🇺🇸
Anthony M. Mills Md Inc, Los Angeles, California, United States
🇺🇸Metropolis Medical Pc, San Francisco, California, United States
🇺🇸Be Well Medical Center, Berkley, Michigan, United States
Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients
- Conditions
- Hypertension
- Interventions
- Drug: Placebo matching with BMS-823778
- First Posted Date
- 2012-05-21
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7
- Registration Number
- NCT01602367
- Locations
- 🇺🇸
Premier Research, Trenton, New Jersey, United States
🇺🇸Pharmquest, Llc, Greensboro, North Carolina, United States
🇺🇸Manassas Clinical Research Center, Manassas, Virginia, United States
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 881
- Registration Number
- NCT01598090
- Locations
- 🇨🇦
Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Mercy Medical Center, Baltimore, Maryland, United States
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
- Conditions
- Chronic Phase Chronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2012-05-08
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 262
- Registration Number
- NCT01593254
- Locations
- 🇺🇸
Northern Indiana Cancer Research Consortium, Crown Point, Indiana, United States
🇺🇸Local Institution - 0006, Fontana, California, United States
🇮🇹Local Institution - 0021, Roma, Italy